This project tests an improved DC vaccine which is designed to promote in vivo cross presentation and determinant spreading. Based on results from our previous trials, we have made several important improvements: engineering the DC with 3 full-length, defined, tumor antigens to activate multiple CD8+ and CD4+ T cell clones (reducing the concern for antigen loss variants);providing antigen presentation for the life of the DC;providing cognate CD4+ T cell help to the CD8+ T cells (""""""""helped"""""""" CTL);using a matured DC (a cocktail specifically matched to adenovirus (AdV) transduction signals);activating innate immunity via NK cell migration and activation;and boosting with systemic IFN? (for endogenous DC type 1 skewing, improved cross-priming and direct effects on T cells). Together, this vaccine strategy should more potently activate a polyclonal anti-tumor response incorporating multiple adaptive and innate effectors which we predict will lead to a higher frequency of patients who not only activate vaccine-encoded antigen-specific T cell responses, but also develop determinant spreading and a significant clinical response. The three aims are:
Aim 1 : Completion of the AdVTMM2/DC +/- IFN? clinical trial 1.a. Clinical outcomes in the stage IV patients;1.b. Immunologic outcomes (from blood and TIL;baseline, post-vaccine and post-IFN?);1.c. AdV-specific cellular and humoral responses.
Aim 2 : Mechanism and biomarkers of clinical response: 2.a. DC Vaccine Transcriptional Profiling (+/- maturation, +/- AdVTMM2);2.b. Tumor Transcriptional Profiling (baseline, post-vaccine and post-IFN?);2.c. Peripheral blood signaling induced by IFN? (STATs);2.d. Serum profiling (autoimmunity antibodies, LDH, CRP cytokines);2.e. Molecular mimicry with mycoplasma (impact of baseline memory to mycoplasma);2.f. Germline DNA SNP analysis Aim 3: Mechanism of NK cell """"""""activation"""""""" in anti-melanoma immunity In vitro studies to expand our recent findings in AdV/DC-NK cell cross-talk with banked melanoma patient blood and tumor (primary tumor expanded to cell lines): 3.a. Direct NK cell interactions with melanoma tumor cells (cytotoxicity, cytokines);3b: Helper/type 1 skewing role in shaping adaptive CD8+ and CD4+ T cell responses;3c: Melanoma tumor impact on NK cell function.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Agarwal, Rajeev K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Anderson, Alyce; Ferris, Laura K; Click, Benjamin et al. (2018) Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. Dig Dis Sci 63:2729-2739
Zhang, Yi; Liu, Zuqiang; Hao, Xingxing et al. (2018) Tumor-derived high-mobility group box 1 and thymic stromal lymphopoietin are involved in modulating dendritic cells to activate T regulatory cells in a mouse model. Cancer Immunol Immunother 67:353-366
Lemchak, David; Banerjee, Swati; Digambar, Shaunak S et al. (2018) Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol 27:188-190
Matsumoto, Martha; Secrest, Aaron; Anderson, Alyce et al. (2018) Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol 78:701-709.e1
Ma, Jing; Salamoun, Joseph; Wipf, Peter et al. (2018) Combination of a thioxodihydroquinazolinone with cisplatin eliminates ovarian cancer stem cell-like cells (CSC-LCs) and shows preclinical potential. Oncotarget 9:6042-6054
Santos, Patricia M; Butterfield, Lisa H (2018) Dendritic Cell-Based Cancer Vaccines. J Immunol 200:443-449
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :
Retseck, Janet; Nasr, Alexis; Lin, Yan et al. (2018) Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. J Transl Med 16:184
Velásquez, Celestino; Amako, Yutaka; Harold, Alexis et al. (2018) Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1. Front Microbiol 9:713
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15

Showing the most recent 10 out of 209 publications